PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-44.59%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-54.72%
Negative gross profit growth while CVE is at 7.61%. Joel Greenblatt would examine cost competitiveness or demand decline.
-96.32%
Negative EBIT growth while CVE is at 40.47%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-96.32%
Negative operating income growth while CVE is at 40.47%. Joel Greenblatt would press for urgent turnaround measures.
-962.12%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-940.30%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-940.30%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
2.25%
Share count expansion well above CVE's 2.59%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
2.25%
Diluted share count expanding well above CVE's 2.88%. Michael Burry would fear significant dilution to existing owners' stakes.
-25.67%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
84.67%
Positive OCF growth while CVE is negative. John Neff would see this as a clear operational advantage vs. the competitor.
57.38%
Positive FCF growth while CVE is negative. John Neff would see a strong competitive edge in net cash generation.
-51.03%
Negative 10Y revenue/share CAGR while CVE stands at 11.77%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-65.61%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-32.54%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
-64.35%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
160.94%
Positive OCF/share growth while CVE is negative. John Neff might see a comparative advantage in operational cash viability.
-24.10%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-5303.17%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-211.83%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-13921.41%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-0.16%
Negative equity/share CAGR over 10 years while CVE stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-47.77%
Negative 5Y equity/share growth while CVE is at 8.75%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
9.13%
3Y equity/share CAGR at 75-90% of CVE's 11.52%. Bill Ackman pushes for margin or operational changes to match the competitor’s pace.
23.02%
Dividend/share CAGR of 23.02% while CVE is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
-75.11%
Both lowered dividends mid-term. Martin Whitman might suspect broad sector constraints or strategic shifts from dividends.
-74.88%
Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.
-48.24%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
68.33%
Inventory growth well above CVE's 2.12%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-7.25%
Negative asset growth while CVE invests at 4.68%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-3.90%
We have a declining book value while CVE shows 6.49%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-3.85%
We’re deleveraging while CVE stands at 9.44%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
-0.48%
We cut SG&A while CVE invests at 7.46%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.